NYSE$HAE
Haemonetics Corp. · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Haemonetics' financial performance reflected agility and resilience in meeting pandemic challenges, with improved plasma collections and customer conversions to NexSys and Persona technologies. Hospital business achieved double-digit growth, marked by a record quarter for Hemostasis Management and Vascular Closure sales. Operational Excellence Program strengthened manufacturing and supply capabilities, significantly improving gross margins.
Haemonetics reported an 8.1% increase in revenue to $259.8 million for the third quarter of fiscal year 2022. Earnings per diluted share were $0.45, and adjusted earnings per diluted share reached $0.84. The company updated its fiscal 2022 revenue growth guidance to 12-14% and organic revenue growth to 5-7%.
- Third-quarter revenue increased by 8.1% to $259.8 million compared to the previous year.
- Earnings per diluted share (EPS) stood at $0.45, while adjusted EPS reached $0.84.
- Gross margin improved to 53.3%, up from 50.0% in the prior year, driven by the Vascular Closure business acquisition and productivity savings.
- The company updated its fiscal 2022 revenue growth guidance to 12-14% and organic revenue growth to 5-7%.
Headline financials
Revenue & EPS history
Haemonetics · Revenue · Quarterly
$260M
Revenue by segment
Haemonetics · $254M total across 3 segments · Q3 2022
- Plasma$96.5M-5.4%37.9%
- Hospital$82.3M+56.3%32.3%
- Blood Center$75.7M-6.5%29.8%
Forward guidance
The Company updated its previous fiscal 2022 GAAP total revenue growth guidance from 13 – 17% to 12 – 14% and its fiscal 2022 organic revenue growth guidance as follows:
Tailwinds
- Total revenue guidance includes $90 - $95 million of revenue related to Vascular Closure.
- Hospital organic revenue guidance includes a Hemostasis Management organic revenue growth rate in the mid-twenties.
- Adjusted operating margin guidance: 18 - 19%
- Adjusted earnings per diluted share guidance: $2.45 - $2.55
- Previous Organic Guidance Total revenue 7 - 10%
Headwinds
- Total revenue organic guidance: 5 - 7%
- Plasma revenue organic guidance: 8 - 10%
- Hospital revenue organic guidance: 16 - 18%
- Blood Center revenue organic guidance: (3 - 5%)
- Free cash flow, before restructuring & restructuring related costs guidance: $110M - $120M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+1.4%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+6.5%
Avg return
30 days after
56%
38 / 68 earnings
Positive
+31.8%
Q2 2026
Best reaction
-15.0%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.3% | +2.5% | +35.5% | |
| Q3 2026 | -1.4% | -9.8% | -2.8% | |
| Q2 2026 | +31.8% | +41.4% | +65.5% | |
| Q4 2025 | +5.9% | +7.6% | +9.7% | |
| Q3 2025 | -11.6% | -13.6% | -3.6% | |
| Q2 2025 | +11.8% | +19.5% | +3.9% | |
| Q1 2025 | -10.1% | -13.4% | -14.6% | |
| Q4 2024 | +2.8% | +4.4% | -8.2% | |
| Q3 2024 | -3.8% | -7.0% | +3.2% | |
| Q2 2024 | +2.4% | +2.5% | -2.5% | |
| Q1 2024 | +2.0% | +3.0% | -0.8% | |
| Q4 2023 | +7.6% | +7.4% | +6.1% | |
| Q3 2023 | -5.4% | -8.2% | -12.2% | |
| Q2 2023 | +4.1% | -1.7% | +3.5% | |
| Q1 2023 | +8.1% | +12.3% | +13.7% | |
| Q4 2022 | +3.9% | +14.1% | +31.5% | |
| Q3 2022 | +21.2% | +24.5% | +18.9% | |
| Q2 2022 | -13.5% | -15.7% | -24.8% | |
| Q1 2022 | +8.4% | +1.8% | +16.8% | |
| Q4 2021 | -6.4% | -5.4% | +0.4% | |
| Q3 2021 | +12.8% | +21.1% | +4.0% | |
| Q2 2021 | -3.7% | +5.6% | +13.2% | |
| Q1 2021 | -12.7% | -8.5% | +3.3% | |
| Q4 2020 | -8.8% | -3.4% | -11.1% | |
| Q3 2020 | +7.2% | +7.7% | -7.3% | |
| Q2 2020 | +0.3% | +0.5% | -0.1% | |
| Q1 2020 | +10.5% | +13.5% | +10.8% | |
| Q4 2019 | +2.8% | +3.4% | +10.0% | |
| Q3 2019 | -12.2% | -14.3% | -13.0% | |
| Q2 2019 | +9.1% | +5.8% | -0.2% | |
| Q1 2019 | +4.8% | +2.7% | +14.4% | |
| Q4 2018 | +5.8% | +11.2% | +18.9% | |
| Q3 2018 | +14.8% | +13.1% | +20.5% | |
| Q2 2018 | +15.8% | +16.4% | +20.8% | |
| Q1 2018 | +4.2% | +3.2% | +3.9% | |
| Q4 2017 | -1.9% | -4.4% | -4.0% | |
| Q3 2017 | -10.1% | -9.0% | -7.3% | |
| Q2 2017 | +10.5% | +13.8% | +16.5% | |
| Q1 2017 | +13.8% | +16.8% | +22.6% | |
| Q4 2016 | -15.0% | — | — | |
| Q3 2016 | +5.9% | — | — | |
| Q2 2016 | -3.9% | — | — | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2015 | -5.9% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | -8.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | -1.4% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -0.1% | — | — | |
| Q4 2012 | +4.2% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q2 2012 | +0.4% | — | — | |
| Q1 2012 | +3.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q4 2009 | +1.3% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2010 | -2.5% | — | — | |
| Q2 2010 | -2.5% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q4 2010 | -2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro